Alnylam Pharmaceuticals, Inc. (ALNY) — Form SCHEDULE 13G/A: Ownership over 5% (passive) (amendment)

Capital Research Global Investors filed an amended Schedule 13G reporting a passive stake in Alnylam Pharmaceuticals, Inc. As of 09/30/2026, the filer beneficially owns 10,940,905 shares, representing 8.2% of the company's common stock.